Phaseline

Targets › CFH

CFH (Complement factor H): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces. (UniProt, P08603)

Open in Phaseline: the race on CFH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Roswell Park Cancer InstituteGT103
anti-CFH monoclonal antibody
CFHPhase 2Advanced Lung Non-Small Cell CarcinomaDec 2028
West China HospitalCFH Protein-loaded Ice Microneedles
Complement factor H (CFH) fragment (human, 860-1231aa) delivered intradermally via ice mic
CFHPhase 1Radiation-Induced Skin FibrosisMar 2027

Conditions

Advanced Lung Non-Small Cell Carcinoma (1) Radiation-Induced Skin Fibrosis (1)

Modalities

antibody (1), protein or peptide (1)

Companies

Roswell Park Cancer Institute (1) West China Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.